Here is the design of a clinical trial:

Official Title: Effect of Fecal Microbiota Transplantation on Primary Hypertension and the Underlying Mechanism of Gut Microbiome Restoration: a Randomized Clinical Trial

Included conditions:
- Hypertension

Study Armgroups:
- {'label': 'FMT capsules', 'type': 'EXPERIMENTAL', 'description': 'Intervention: FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).', 'interventionNames': ['Biological: FMT capsules']}
- {'label': 'Placebo capsules', 'type': 'PLACEBO_COMPARATOR', 'description': 'Intervention: Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).', 'interventionNames': ['Other: Placebo capsules']}

Interventions:
- {'type': 'BIOLOGICAL', 'name': 'FMT capsules', 'description': 'Intervention: FMT capsules containing extensively screened donor stool.', 'armGroupLabels': ['FMT capsules']}
- {'type': 'OTHER', 'name': 'Placebo capsules', 'description': 'Intervention: Placebo capsules that do not contain donor stool or any active drug.', 'armGroupLabels': ['Placebo capsules']}

Primary Outcomes:
- {'measure': 'Change for Office Systolic Blood Pressure (SBP)', 'description': 'Change for Office Systolic Blood Pressure (SBP)', 'timeFrame': 'From baseline to Day 30'}

Please estimate the sample size based on the assumption: 
Statistical power of > 80% to demonstrate a > 5 mmHg difference between arms at a 1-sided alpha level of 0.025, with a 20% rate of loss-of-follow-up considered.
Sample size {14}
          Sample size calculation was performed via PASS version 15 software before trial initiation based on the following: (1) no relevant current data for the effect of FMT on hypertension; (2) a clinically significant improvement of a decrease in office SBP at least 5âmmHg associated with reduction in stroke (14%), cardiovascular disease (9%), and mortality (7%) [32]; (3) meta-analysis of the effectiveness of probiotics on hypertension based on randomized controlled clinical trials that revealed a reduction of SBP of 3.56âmmHg (95% CI, 6.46 to 0.66) [33]. Assuming a true SBP difference between the âFMT capsule groupâ and âplacebo groupâ with a mean of 5âmmHg and a standard deviation of 8.6âmmHg for SBP change per arm, a sample size of 96 grade one hypertensive patients yields >â80% statistical power to demonstrate a > 5âmmHg difference between arms at a 1-sided alpha level of 0.025. Given the potential for premature withdrawal or failure before the primary end point data were collected, a 20% rate of loss-of-follow-up was considered, resulting in 120 participants with grade one hypertension according to the â2010 Chinese Guidelines for Prevention and Treatment of Hypertensionâ [28]. Participants were recruited and randomized 1:1 to receive FMT by capsule or placebo capsules.